These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38416360)

  • 1. Hand2 Immunohistochemistry in the Diagnosis of Paragangliomas and Other Neuroendocrine Neoplasms.
    Soukup J; Manethova M; Stejskal V; Novakova M; Duskova J; Hornychova H; Hacova M; Staniczkova-Zambo I; Zelinka T; Kosak M; Cesak T; Netuka D; Ryska A; Gabalec F
    Endocr Pathol; 2024 Mar; 35(1):14-24. PubMed ID: 38416360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phox2B is a sensitive and reliable marker of paraganglioma-Phox2B immunohistochemistry in diagnosis of neuroendocrine neoplasms.
    Manethova M; Gerykova L; Faistova H; Drugda J; Hacova M; Hornychova H; Ryska A; Gabalec F; Soukup J
    Virchows Arch; 2023 Apr; 482(4):679-686. PubMed ID: 36656393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors.
    Soukup J; Manethova M; Stejskal V; Hornychova H; Cesak T; Netuka D; Ryska A; Gabalec F
    Endocr Pathol; 2023 Sep; 34(3):333-341. PubMed ID: 37552455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cauda equina neuroendocrine tumors show biological features distinct from other paragangliomas and visceral neuroendocrine tumors.
    Soukup J; Manethova M; Kohout A; Soukup T; Dvorakova R; Drugda J; Vitovcova B; Gabalec F; Kaiser M; Kanta M; Kasparova P; Kozak J; Michnova L; Netuka D; Reguli S; Rychly B; Trnkova M; Vachata P; Wozniakova M; Cesak T
    Virchows Arch; 2023 Feb; 482(2):325-338. PubMed ID: 36348031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of PHOX2B in adult neuroendocrine neoplasms reveals relatively frequent expression in phaeochromocytomas and paragangliomas.
    Lee JP; Hung YP; O'Dorisio TM; Howe JR; Hornick JL; Bellizzi AM
    Histopathology; 2017 Oct; 71(4):503-510. PubMed ID: 28464318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHOX2B is a Sensitive and Specific Marker for the Histopathological Diagnosis of Pheochromocytoma and Paraganglioma.
    Miyauchi M; Akashi T; Furukawa A; Uchida K; Tamura T; Ando N; Kirimura S; Shintaku H; Yamamoto K; Ito T; Miura K; Kayamori K; Ariizumi Y; Asakage T; Kudo A; Tanabe M; Fujii Y; Ishibashi H; Okubo K; Murakami M; Yamada T; Takemoto A; Bae Y; Eishi Y; Ohashi K
    Endocr Pathol; 2022 Dec; 33(4):506-518. PubMed ID: 36029394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
    Bellizzi AM
    Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical distinction of paragangliomas from epithelial neuroendocrine tumors-gangliocytic duodenal and cauda equina paragangliomas align with epithelial neuroendocrine tumors.
    Mamilla D; Manukyan I; Fetsch PA; Pacak K; Miettinen M
    Hum Pathol; 2020 Sep; 103():72-82. PubMed ID: 32668278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
    Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
    Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcription Factor Expression in Sinonasal Neuroendocrine Neoplasms and Olfactory Neuroblastoma (ONB): Hyams' Grades 1-3 ONBs Expand the Spectrum of SATB2 and GATA3-Positive Neoplasms.
    Uccella S; Facco C; Chiaravalli AM; Pettenon F; La Rosa S; Turri-Zanoni M; Castelnuovo P; Cerati M; Sessa F
    Endocr Pathol; 2022 Jun; 33(2):264-273. PubMed ID: 35522392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.
    Rindi G; Mete O; Uccella S; Basturk O; La Rosa S; Brosens LAA; Ezzat S; de Herder WW; Klimstra DS; Papotti M; Asa SL
    Endocr Pathol; 2022 Mar; 33(1):115-154. PubMed ID: 35294740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitx2 is a useful marker of midgut-derived neuroendocrine tumours - an immunohistochemical study of 224 cases.
    Soukup J; Manethova M; Faistova H; Krbal L; Vitovcova B; Hornychova H; Drugda J; Cesak T; Netuka D; Gabalec F; Ryska A
    Histopathology; 2022 Dec; 81(6):799-807. PubMed ID: 36089904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma-paraganglioma origin.
    Remes SM; Leijon H; Vesterinen T; Louhimo J; Pulkkinen V; Ezer S; Kere J; Haglund C; Arola J
    APMIS; 2020 Nov; 128(11):563-572. PubMed ID: 32794589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of gata3 and phox2b expression in tumors of the autonomic nervous system.
    Nonaka D; Wang BY; Edmondson D; Beckett E; Sun CC
    Am J Surg Pathol; 2013 Aug; 37(8):1236-41. PubMed ID: 23715162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Metastatic Patterns Among Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Nonneuroendocrine Carcinomas of Various Primary Organs.
    Park HK; Kwon GY
    J Korean Med Sci; 2023 Mar; 38(11):e85. PubMed ID: 36942393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors.
    Li B; Li X; Mao R; Liu M; Fu L; Shi L; Zhao S; Fu M
    Endocr Pathol; 2021 Jun; 32(2):301-308. PubMed ID: 32869188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long Non-coding RNAs in Pulmonary Neuroendocrine Neoplasms.
    Narayanan D; Mandal R; Hardin H; Chanana V; Schwalbe M; Rosenbaum J; Buehler D; Lloyd RV
    Endocr Pathol; 2020 Sep; 31(3):254-263. PubMed ID: 32388776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cauda Equina Neuroendocrine Tumors: Distinct Epithelial Neuroendocrine Neoplasms of Spinal Origin.
    Asa SL; Mete O; Schüller U; Ramani B; Mirchia K; Perry A
    Am J Surg Pathol; 2023 Apr; 47(4):469-475. PubMed ID: 36543154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity.
    Schweizer L; Thierfelder F; Thomas C; Soschinski P; Suwala A; Stichel D; Wefers AK; Wessels L; Misch M; Kim HY; Jödicke R; Teichmann D; Kaul D; Kahn J; Bockmayr M; Hasselblatt M; Younsi A; Unterberg A; Knie B; Walter J; Al Safatli D; May SA; Jödicke A; Ntoulias G; Moskopp D; Vajkoczy P; Heppner FL; Capper D; Hartmann W; Hartmann C; von Deimling A; Reuss DE; Schöler A; Koch A
    Acta Neuropathol; 2020 Dec; 140(6):893-906. PubMed ID: 32926213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Claudin 18.2 expression in digestive neuroendocrine neoplasms: a clinicopathological study.
    Jiang K; Cao F; Yin L; Hu Y; Zhao X; Huang X; Ma X; Li J; Lu M; Sun Y
    J Endocrinol Invest; 2024 May; 47(5):1251-1260. PubMed ID: 38060154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.